Search research articles
Contact Us
Filters
Showing results (321-330 of 484) with videos related to
Page
of 49
Sort By:
Diabetes, Obesity & Metabolism
|
February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial
Jennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
Diabetes Care
|
June 25, 2015
Erratum. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295-303
Graham S Hillis, Paul Welsh, John Chalmers, et al.
Journal of the American College of Cardiology
|
November 27, 2010
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial
G David Batty, Qiang Li, Sébastien Czernichow, et al.
Sleep
|
February 12, 2015
The Sleep Apnea cardioVascular Endpoints (SAVE) Trial: Rationale, Ethics, Design, and Progress
Nick A Antic, Emma Heeley, Craig S Anderson, et al.
The American Journal of Clinical Nutrition
|
March 30, 2021
Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial
Jie Yu, Sudhir Raj Thout, Qiang Li, et al.
The Lancet. Rheumatology
|
January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
JingWei Li, Sunil V Badve, Zien Zhou, et al.
Journal of the American Heart Association
|
January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Clare Arnott, Qiang Li, Amy Kang, et al.
Diabetes Care
|
October 4, 2013
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes
Graham S Hillis, Paul Welsh, John Chalmers, et al.
Diabetes Care
|
September 22, 2022
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Akihiko Koshino, Meir Schechter, Taha Sen, et al.
The Lancet. Public Health
|
November 1, 2024
Estimated health benefits, costs, and cost-effectiveness of implementing WHO's sodium benchmarks for packaged foods in India: a modelling study
Kathy Trieu, Liping Huang, Leopold N Aminde, et al.
Page
of 49
Search research articles
Search
Showing results (321-330 of 484) with videos related to
Sort By:
Page
of 49
Diabetes, Obesity & Metabolism
|
February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial
Jennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
Diabetes Care
|
June 25, 2015
Erratum. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295-303
Graham S Hillis, Paul Welsh, John Chalmers, et al.
Journal of the American College of Cardiology
|
November 27, 2010
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial
G David Batty, Qiang Li, Sébastien Czernichow, et al.
Sleep
|
February 12, 2015
The Sleep Apnea cardioVascular Endpoints (SAVE) Trial: Rationale, Ethics, Design, and Progress
Nick A Antic, Emma Heeley, Craig S Anderson, et al.
The American Journal of Clinical Nutrition
|
March 30, 2021
Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial
Jie Yu, Sudhir Raj Thout, Qiang Li, et al.
The Lancet. Rheumatology
|
January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
JingWei Li, Sunil V Badve, Zien Zhou, et al.
Journal of the American Heart Association
|
January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Clare Arnott, Qiang Li, Amy Kang, et al.
Diabetes Care
|
October 4, 2013
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes
Graham S Hillis, Paul Welsh, John Chalmers, et al.
Diabetes Care
|
September 22, 2022
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Akihiko Koshino, Meir Schechter, Taha Sen, et al.
The Lancet. Public Health
|
November 1, 2024
Estimated health benefits, costs, and cost-effectiveness of implementing WHO's sodium benchmarks for packaged foods in India: a modelling study
Kathy Trieu, Liping Huang, Leopold N Aminde, et al.
Page
of 49